The anti-atherosclerotic effect of tanshinone IIA is associated with the inhibition of TNF-α-induced VCAM-1, ICAM-1 and CX3CL1 expression

Tanshinone II A Attenuates TNF-α-Induced Expression of VCAM-1 and ICAM-1 in Endothelial Progenitor Cells by Blocking Activation of NF-κB

“…Tang et al found that Tan IIA pretreatment inhibits the expression of VCAM-1 and ICAM-1, and decreases TNF-α-induced adhesion of neutrophils to brain microvascular endothelial cells in a dose-dependent manner [28]. Chang et al also found that Tan IIA can suppress TNF-α-induced expression of VCAM-1 and ICAM-1 in human vascular endothelial cells [10].…”

“…VCAM-1 and ICAM-1 were showed to be expressed by EPCs and play a critical role in the atherosclerosis [10][11][12]. The circulating EPCs may stick MNCs through VCAM-1 and ICAM-1 and format EPC-MNC adhesion.…”

“…In this paper, we tried to examine the ability of Tan IIA to modulate the expression of adhesion molecules by TNF-α-induced EPCs. Nuclear factor κB (NF-κB) serves as a transcription factor and the nuclear translocation of NF-κB after inflammatory stimulation is essential to induce subsequent immune response [10]. So, we also attempted to find out whether the modulation is NF-κB dependent.…”

TNF-α-mediated adhesion of monocytes to endothelial cells—The role of ephrinA1

“…The impact of TNF-α on monocyte adhesion to the endothelium is well known: TNF-α stimulation of endothelial cells leads to an activation of NFκB followed by a transcriptional activation of several adhesion molecules, like VCAM-1, ICAM-1 and E-Selectin [34,35]. Besides the transcriptional activation of adhesion molecules, TNF-α is able to induce cytoskeletal changes leading to the clustering of adhesion receptors on the surface of endothelial cells [36], which demonstrates the multifunctional influence of TNF-α on monocyte adhesion.…”

Sodium tanshinone IIA sulfonate prevents lipopolysaccharide-induced inflammation via suppressing nuclear factor-κB signaling pathway in human umbilical vein endothelial cells

“…Sodium tanshinone IIA sulfonate (STS, molecular structure shown in Wu et al 2009), inhibit inflammatory response (Li et al 2015;Lu et al 2016;Yang et al 2016) and prevent atherosclerosis (Chang et al 2014;Chen et al 2012;Chen and Xu 2014;Fang et al 2008) as well as cardiac injury (Gao et al 2012;Jiang et al 2009) and hypertrophy (Feng and Zheng 2008;Weng et al 2015;Yang et al 2007). Tanshinone IIA has also been reported to prevent LPS-induced inflammation response in acute lung injury (Xu et al 2015) and in RAW264.7 macrophages (Fan et al 2016;Jang et al 2006) via inhibition of the NF-κB pathway.…”